These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30145210)

  • 1. Enhancing the Dissolution Stability of Hard Gelatin Capsules Using Activated Carbon as a Packaging Component.
    Likar MD; Carroll SC; Colgan ST; Yeoh T; MacDonald BC; Johnson GM; Space JS
    J Pharm Sci; 2018 Dec; 107(12):3080-3088. PubMed ID: 30145210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Activated Carbon in Packaging to Attenuate Formaldehyde-Induced and Formic Acid-Induced Degradation and Reduce Gelatin Cross-Linking in Solid Dosage Forms.
    Colgan ST; Zelesky TC; Chen R; Likar MD; MacDonald BC; Hawkins JM; Carroll SC; Johnson GM; Space JS; Jensen JF; DeMatteo VA
    J Pharm Sci; 2016 Jul; 105(7):2027-31. PubMed ID: 27262203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosslinking studies in gelatin capsules treated with formaldehyde and in capsules exposed to elevated temperature and humidity.
    Ofner CM; Zhang YE; Jobeck VC; Bowman BJ
    J Pharm Sci; 2001 Jan; 90(1):79-88. PubMed ID: 11064381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of capsule shell composition on the performance indicators of hypromellose capsule in comparison to hard gelatin capsules.
    Al-Tabakha MM; Arida AI; Fahelelbom KM; Sadek B; Saeed DA; Abu Jarad RA; Jawadi J
    Drug Dev Ind Pharm; 2015; 41(10):1726-37. PubMed ID: 25586554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of glycine/citric acid on the dissolution stability of hard gelatin capsules.
    Adesunloye TA; Stach PE
    Drug Dev Ind Pharm; 1998 Jun; 24(6):493-500. PubMed ID: 9876614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of correlation between gelatin crosslinking indicators and influence factors].
    Liu JP; Ma X; Zhu JB
    Yao Xue Xue Bao; 2005 Mar; 40(3):279-84. PubMed ID: 15952604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of hard gelatin capsule shells filled with polyethylene glycol matrices.
    Stein D; Bindra DS
    Pharm Dev Technol; 2007; 12(1):71-7. PubMed ID: 17484146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance.
    Digenis GA; Gold TB; Shah VP
    J Pharm Sci; 1994 Jul; 83(7):915-21. PubMed ID: 7965669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fill weight, capsule shell, and sinker design on the dissolution behavior of capsule formulations of a weak acid drug candidate BMS-309403.
    Wu Y; Zhao F; Paborji M
    Pharm Dev Technol; 2003; 8(4):379-83. PubMed ID: 14601962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gelatin and Non-Gelatin Capsule Dosage Forms.
    Gullapalli RP; Mazzitelli CL
    J Pharm Sci; 2017 Jun; 106(6):1453-1465. PubMed ID: 28209365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture.
    Digenis GA; Sandefer EP; Page RC; Doll WJ; Gold TB; Darwazeh NB
    Pharm Res; 2000 May; 17(5):572-82. PubMed ID: 10888309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vitro dissolution of theophylline from different types of hard shell capsules.
    Podczeck F; Jones BE
    Drug Dev Ind Pharm; 2002 Oct; 28(9):1163-9. PubMed ID: 12455475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release.
    Marchais H; Cayzeele G; Legendre JY; Skiba M; Arnaud P
    Eur J Pharm Sci; 2003 Jun; 19(2-3):129-32. PubMed ID: 12791415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The shell dissolution of various empty hard capsules.
    Chiwele I; Jones BE; Podczeck F
    Chem Pharm Bull (Tokyo); 2000 Jul; 48(7):951-6. PubMed ID: 10923822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymes in the dissolution testing of gelatin capsules.
    Marques MR
    AAPS PharmSciTech; 2014 Dec; 15(6):1410-6. PubMed ID: 24942315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retarded dissolution of ibuprofen in gelatin microcapsule by cross-linking with glutaradehyde.
    Yong CS; Li DX; Oh DH; Kim JA; Yoo BK; Woo JS; Rhee JD; Choi HG
    Arch Pharm Res; 2006 Jun; 29(6):520-4. PubMed ID: 16833022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etodolac-liquid-filled dispersion into hard gelatin capsules: an approach to improve dissolution and stability of etodolac formulation.
    Barakat NS
    Drug Dev Ind Pharm; 2006 Aug; 32(7):865-76. PubMed ID: 16908424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection.
    Lu X; Xiao B; Lo L; Bolgar MS; Lloyd DK
    J Pharm Biomed Anal; 2011 Aug; 56(1):23-9. PubMed ID: 21620602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative Manufacturing Concepts for Solid Oral Dosage Forms From Drug Nanosuspensions Using Fluid Dispensing and Forced Drying Technology.
    Bonhoeffer B; Kwade A; Juhnke M
    J Pharm Sci; 2018 Mar; 107(3):909-921. PubMed ID: 29154900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of extent of formaldehyde-induced crosslinking in hard gelatin capsules by near-infrared spectrophotometry.
    Gold TB; Buice RG; Lodder RA; Digenis GA
    Pharm Res; 1997 Aug; 14(8):1046-50. PubMed ID: 9279887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.